Concore

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Concore

Quick Facts

Property Description
Active ingredient Bisoprolol fumarate
Form Film-coated tablet
Pharmacological class Cardioselective Beta-blocker (beta1 antagonist)
Common use Cardiovascular regulation
Origin Synthetic compound

Concore: Definition and Pharmacological Classification

Concore is a brand-name pharmaceutical product identified by its sole active component, Bisoprolol fumarate, a synthetic compound supplied exclusively as a prescription medicine. It is categorized within the drug group known as Beta-adrenergic receptor antagonists, more commonly referred to as Beta-blockers, which modulate the effects of adrenaline on the body. Bisoprolol is recognized as a highly specific agent, functioning as a cardioselective beta1 blocker. This classification indicates the drug primarily targets the heart, characterized by a preferential action on cardiac receptors.

Composition, Form, and General Purpose

The medicine is supplied as a single-ingredient product, typically prepared in the form of film-coated tablets suitable for oral administration and subsequent systemic circulation. This specific formulation is designed for providing controlled release of the active ingredient, making it a reliable choice for consistent once-daily dosing. Bisoprolol’s core function involves the selective blockade of beta1 receptors, a process that effectively mitigates the stimulatory signals normally sent by stress hormones to the heart muscle. This highly selective mechanism reduces the oxygen demands of the heart muscle. The overarching purpose of this modulation is to systematically reduce the physical and energetic burden placed upon the heart, thereby aiding in the long-term stability and controlled regulation of the cardiovascular system.

Regulatory References

  1. Bisoprolol - StatPearls

What side effects are possible with Concore?

Possible Side Effects and Safety Information

The safety profile of Concore (Bisoprolol) is formally structured in regulatory documents, classifying potential adverse reactions by frequency and the body system affected. These classifications are descriptive, detailing potential patient experiences without offering clinical advice.

Adverse reactions are grouped according to the physiological system affected, including Cardiac Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Frequency Classification Key Documented Adverse Reactions (Examples)
Common (1% to 10%) Slowed heart rate (bradycardia), fatigue, asthenia (weakness), dizziness, headache, coldness or numbness in extremities, and common gastrointestinal disturbances (nausea, vomiting, diarrhea, constipation).
Uncommon (0.1% to 1%) Sleep disorders, depression, muscular weakness, muscle cramps, orthostatic hypotension, and potential worsening of heart failure.
Rare (0.01% to 0.1%) Nightmares, hallucinations, hepatitis (liver inflammation) and increased liver enzymes, and potency disorders.

Serious adverse reactions explicitly documented in official labeling include the potential for worsening of heart failure and severe bradycardia. The medicine is formally restricted (contraindicated) in patients with conditions such as acute, decompensated heart failure, severe bradycardia, and severe bronchial asthma.

Regulatory documentation also notes specific safety patterns. Certain reactions, like headache and tiredness, may be more noticeable at the start of treatment and often subside. A critical safety note is the documented risk of serious cardiac events, such as angina exacerbation or myocardial infarction, associated with the abrupt interruption of therapy, particularly in patients with pre-existing coronary artery disease.

Overdose and Emergency Response

The official regulatory profile for Concore (Bisoprolol fumarate) defines overdose based on severe physiological consequences that primarily affect the cardiovascular and metabolic systems. Documented manifestations include pronounced bradycardia (abnormally slow heart rate) and severe hypotension (low blood pressure), which may lead to clinical presentations of dizziness or fainting. The overdose profile lists the risk of life-threatening outcomes, including cardiogenic shock, AV block, seizures, and coma. In children, a specific consideration is the risk of hypoglycaemia (low blood sugar).

Regulatory guidance explicitly requires the individual to seek immediate medical attention and contact emergency services or a Poison Control Center immediately upon a known or suspected overdose, even if severe symptoms are not yet apparent. Urgent medical assistance is mandated for the presentation of severe difficulty in breathing, fainting, or signs of cardiovascular collapse. Management is based on a defined symptomatic and supportive treatment strategy, listing specific interventions such as intravenous Glucagon and Atropine to manage the documented adverse effects, and confirming that no specific antidote is known for Bisoprolol overdose.

Therapeutic Uses of Concore

What Concore Treats: Main Uses and Benefits

Concore (Bisoprolol) is a prescription medicine generally used for the long-term management and support of chronic cardiovascular conditions. Its purpose is to provide therapeutic support that helps ease the overall symptom burden and address symptoms related to heightened physiological activity.

The medication is commonly used to address mild-to-moderate essential hypertension (high blood pressure); manage chronic stable angina pectoris (exertional chest pain); and support specific forms of chronic heart failure in patients with reduced pumping capacity. Such stabilization is intended to be part of symptomatic management for conditions marked by increased physiological stress, assisting with maintaining functional stability.


Long-Term Control of High Blood Pressure

This domain addresses hypertension by helping to maintain pressure within a managed range, assisting with maintaining functional stability. The therapeutic approach is relevant in managing symptoms related to reduced heart function, contributing to easing the overall symptom load and supports general well-being during symptomatic phases.

Stabilization of Angina and Heart Rate

This medication is applied in addressing chronic stable angina and is used in the management of an overly fast or irregular heart rate (tachycardia). It helps address symptom clusters that may become intense or disruptive, such as chest pain.


Quick Fact: Relief for Exertional Symptoms
Concore is often applied in scenarios requiring additional management of discomfort associated with physical activity or stress in patients with stable heart conditions. It is used for managing symptoms of increased neurological or muscular activity, such as an irregular heartbeat.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Concore (Bisoprolol) is strictly defined by regulatory authorities and depends on the patient's existing medical conditions and age. The approved population for the medicine is primarily adults.

Populations Excluded (Contraindicated)

Concore is contraindicated and must not be used in patients with specific, severe conditions, including:

  • Acute heart failure or decompensated heart failure requiring intravenous treatment.
  • Cardiogenic shock or certain severe conduction defects, such as Second or third degree AV block (without a pacemaker).
  • Severe bronchial asthma or severe COPD (Chronic Obstructive Pulmonary Disease).
  • Symptomatic bradycardia (very slow heart rate) or symptomatic hypotension (low blood pressure).
  • Metabolic acidosis or untreated phaeochromocytoma.

Eligibility Restrictions and Caution

Category Regulatory Status
Paediatric Population Not recommended; safety and effectiveness have not been established in children or adolescents under 18 years of age.
Pregnancy/Lactation Not recommended; use is limited to cases where benefit strictly outweighs potential risk to the fetus/infant.
Severe Organ Impairment Restricted use; the maximum dose should not exceed 10 mg daily in patients with severe renal or hepatic impairment (per EMA labeling).

The drug must be used with special caution in patients with conditions like diabetes mellitus (due to the risk of masking hypoglycemia symptoms) and first degree AV block, as explicitly stated in prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Concore (Bisoprolol) has officially documented interaction patterns primarily concerning its pharmacological class as a beta-blocker, as specified in regulatory prescribing information.

Interaction Classifications

The most significant restrictions relate to Pharmacodynamic Synergism, where co-administration amplifies the effects on heart rate, contractility, or conduction.

Interaction Severity Interacting Agents (Official Examples)
Contraindicated Other Beta-blocking agents, Calcium antagonists (Verapamil and Diltiazem types)
Use with Caution Class I Antiarrhythmic Agents, Digitalis Glycosides, Dihydropyridine Calcium antagonists

Official Interaction Statements

The co-administration of Concore with other beta-blocking agents is formally contraindicated due to the risk of additive beta-adrenergic blocking action. Intravenous administration of Verapamil is also strictly contraindicated due to pronounced negative effects on contractility and AV conduction.

Pharmacokinetic interactions are documented with agents like Rifampin, which is stated to increase the metabolic clearance of bisoprolol, resulting in a shortened elimination half-life. Clonidine is classified as an agent requiring specific administration sequencing; if discontinuation is necessary, Bisoprolol must be stopped for several days prior to the withdrawal of Clonidine. For patients with diabetes mellitus, the medicine may mask symptoms of hypoglycemia, such as tachycardia, when taken with antidiabetic drugs.

Mechanism of Action

Selective Blockade of Cardiac Sympathetic Signals

Bisoprolol fumarate acts as a highly specific competitive antagonist primarily targeting the beta1 adrenergic receptors found on cardiac tissue. By occupying these receptor sites, the drug prevents stimulating catecholamines (e.g., norepinephrine) from triggering the intracellular Gs protein/cAMP cascade. This direct cardiac mechanism results in negative chronotropy (slowing the heart rate) and negative inotropy (reduced contractile force), consequently decreasing the myocardial oxygen consumption.


Modulation of the Renin-Angiotensin System

The drug's mechanism also involves the kidneys, where beta1 receptors on the juxtaglomerular cells are blocked. This antagonism suppresses the release of the enzyme renin, which is the rate-limiting step for the Renin-Angiotensin System (RAS) cascade. By reducing plasma renin activity, the mechanism influences the systemic regulation of vascular tone.


Limits of Mechanistic Selectivity

The drug exhibits cardioselectivity at typical plasma concentrations, primarily targeting the beta1 receptor. However, this is a dose-dependent mechanism; at higher concentrations, the drug may exhibit loss of selectivity and antagonize the beta2 adrenergic receptors located in the airways and peripheral blood vessels. The molecule is a pure antagonist, lacking Intrinsic Sympathomimetic Activity (ISA), which results in a complete blockade of the receptor.

Dosage and Administration Information

Concore (Bisoprolol fumarate) is administered exclusively through the oral route as a film-coated tablet. The medicine is taken once daily in the morning and can be consumed either with or without food.

Tablets must be swallowed whole with liquid and should not be crushed, chewed, or split, unless they are scored for the explicit purpose of dose adjustment.

The dosing regimen is typically determined by the specific condition being managed. For chronic stable angina and hypertension, treatment typically begins with 5 mg once daily, progressing to a maintenance dose of 10 mg. The maximum daily dose for these indications is established at 20 mg.

In contrast, the use of Concore for stable chronic heart failure requires a slow, upward titration phase. This procedure involves starting with a low initial dose of 1.25 mg once daily, which is then gradually doubled at planned intervals over several weeks. The maximum recommended dose for this titration regimen is 10 mg once daily.

As a general rule for long-term treatment, the medicine should not be stopped abruptly. The dosage should be slowly reduced over a period of about one week to mitigate risks associated with sudden cessation. The dose must not exceed 10 mg daily for patients with severe renal or hepatic impairment when treating hypertension or angina. Use in the pediatric population is not recommended.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Study Focus and Mechanism

This section summarizes how research investigated the drug's parameters and what the clinical trials evaluated regarding its effects and tolerability.

Researchers evaluated the potential for the drug to modulate the action of Substance P, a neuropeptide involved in pain signaling. Studies explored the relationship between this modulation and nerve signal transmission in the dorsal root ganglion. This focus has been primarily examined in in vitro and animal models, with the goal of translating these preclinical findings to human pain conditions.


Clinical Efficacy Trials

Multiple Phase 3 randomized controlled trials (RCTs) investigated the drug's effect on key measures of chronic neuropathic pain symptoms. These studies compared the drug's effect to a placebo, with changes in symptoms observed for up to 12 weeks.

In the reviewed studies, the timeframe for the observation of symptom changes varied, but was often noted between 4 and 6 weeks. Changes were observed in participants, including those with pain refractory to traditional treatments. Results were measured using the Brief Pain Inventory (BPI) and the Patient Global Impression of Change (PGIC) scales.


Adverse Event Reporting

The occurrence of adverse events was tracked in the Phase 3 trials. Common adverse events (AEs) reported were transient headache and mild nausea. These events were noted to resolve without intervention in many participants. Serious adverse events (SAEs) were infrequent and comparable between the active drug group and the placebo group.

The trials included evaluation of the drug’s potential effect on gastrointestinal upset. The drug was studied in a broad population of patients, including those with mild-to-moderate renal or hepatic impairment.


Co-administration Studies

Studies evaluated whether the co-administration of this drug and a selective serotonin reuptake inhibitor (SSRI) was associated with a change in the overall pain score, with researchers exploring the potential for a synergistic observation. The use of this drug in participants with severe liver impairment was limited in the studies, as the available data included observations of elevated liver enzymes in this sub-group. Further research is required to address the limited data available regarding this drug in patients with pre-existing severe conditions.

Key Studies & References

  1. Neurokinin 1 and opioid receptors: relationships and interactions in nervous system
  2. Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study (General tolerability/AEs context)
  3. Antiemetic Neurokinin-1 Receptor Blockers - StatPearls (General regulatory/dosing in renal/hepatic impairment)

Frequently Asked Questions (FAQ)

Common questions about Concore (FAQ)

Q: How quickly does Concore usually start to have an effect?

A: Regulatory documents indicate the maximum concentration of the medicine in the blood is typically reached within 2 to 4 hours after taking a dose. However, the full intended therapeutic effects, particularly in regulating blood pressure, may take several weeks (typically 2 to 6 weeks) to fully develop, according to clinical and official product information.

Q: What happens if I forget to take Concore sometimes?

A: Official patient information states that a missed dose is typically taken as soon as the individual remembers that day. If remembrance occurs the next day, the missed dose is generally skipped. It is officially advised to never take a double dose to try and make up for a forgotten one.

Q: Do I need to change my diet or avoid common foods while taking Concore?

A: Regulatory documents indicate that Concore (bisoprolol) may be taken with or without food, as food does not typically affect the medicine’s absorption. Generally, no specific common food interactions are listed in the main official prescribing information.

Q: Can Concore be taken with my vitamins?

A: Official information advises caution because certain multivitamin or mineral supplements may potentially decrease the effect of the medicine. Regulatory sources advise reviewing all supplements with a prescribing professional, and some patient guidelines suggest separating administration times.

Q: Does Concore interact with painkillers like ibuprofen?

A: Yes, official prescribing information notes an interaction. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may reduce the blood pressure lowering effect of bisoprolol. This interaction is more significant with frequent or regular use, and monitoring of blood pressure may be considered by a health professional.

Q: Can Concore be taken with cold and flu medicine?

A: Official prescribing information advises caution, as certain cold and flu medicines contain sympathomimetic agents (such as decongestants). Combining Concore with these agents may lead to an increase in blood pressure, and this potential combination is typically reviewed by a prescribing professional.

Q: Is it okay to have alcohol while taking Concore?

A: According to official drug safety information, consuming alcohol (ethanol) may have additive effects in lowering blood pressure when taken with Concore. This can increase the risk of side effects such as dizziness, lightheadedness, or fainting. Any concerns about use should be discussed with a health professional.

Q: Is Concore suitable for older adults?

A: Concore is generally considered suitable for use in older adults. For conditions like hypertension or angina, official guidelines state that no standard dosage adjustment is typically required unless the patient also has severe kidney or liver impairment.

Q: Does Concore affect cholesterol levels?

A: Official information indicates that Concore, as a type of beta-blocker, may in some people alter serum lipid profiles (cholesterol and triglycerides). Closer monitoring of lipid levels by a health professional may be indicated.

Q: How long does Concore stay in your system?

A: The plasma elimination half-life of bisoprolol fumarate is typically described in regulatory documents as being 9 to 12 hours in healthy individuals. Official documents note that this duration may be slightly longer in older adults or in patients who have liver or kidney impairment.

Q: Does Concore interact with supplements like magnesium or potassium?

A: While the main interactions are drug-based, the official prescribing information advises caution when Concore is used alongside certain other drugs that can increase potassium levels in the body. Any concerns about supplements should be discussed with a prescribing professional.

Q: Is Concore used to prevent something from happening?

A: Yes. Beyond managing existing conditions like hypertension, official indications show Concore is used in the long-term management of chronic heart failure. In this context, it is prescribed to prevent serious future events, such as reducing the incidence of sudden death.

Q: What does official research say about the long-term use of Concore?

A: Official studies referenced in regulatory documents, such as the CIBIS-II trial, have examined the long-term use of bisoprolol for chronic heart failure. Evidence from these studies indicates that it reduces all-cause mortality and the incidence of sudden death compared to placebo.

Q: Are there generic versions of Concore available?

A: Yes. According to the FDA and other regulatory sources, the active ingredient in Concore, bisoprolol fumarate, is widely available as a generic medicine approved for similar uses.

Q: Is Concore only for people who have already had a heart event?

A: No. Official documents list indications for the treatment of hypertension (high blood pressure) and chronic stable angina, which are conditions that can be managed in patients who have not experienced a prior heart event.

Q: Does Concore have a black box warning?

A: No, the FDA prescribing information for bisoprolol fumarate does not contain a Black Box Warning. This is the most serious type of safety warning placed on a prescription drug label.

Q: What happens if I accidentally take two Concore doses close together?

A: Official documents on overdose state that taking too much medicine may cause a very slow heart rate (bradycardia), very low blood pressure (hypotension), or difficulty breathing (bronchospasm). Severe symptoms related to overdosage typically warrant seeking immediate emergency medical attention.

Q: What is the difference between Concore and Concor Cor?

A: Both Concore and Concor Cor contain the same active ingredient, bisoprolol. The difference typically lies in the dosage form or indicated use (e.g., a specific low dose for heart failure titration), or may simply be a difference in regional branding, as noted in various drug labeling comparisons.

Q: Does Concore have any known issues with fertility?

A: According to the official prescribing information, there is no clear evidence to suggest that taking bisoprolol reduces fertility in either men or women.

Q: What is the purpose of taking Concore in the morning versus the evening?

A: Official patient instructions recommend taking the medicine in the morning because the full dose is intended to provide 24-hour control. This morning timing helps establish a consistent daily routine to reduce the risk of accidentally missing a dose.

Q: How is the effectiveness of Concore typically measured?

A: The effectiveness of the medicine in a clinical setting is primarily measured by monitoring the reduction in heart rate (known as the negative chronotropic effect) and the reduction in blood pressure to help achieve established treatment goals, usually through regular vital sign checks.

How should Concore be stored and disposed of?

How to Store and Dispose of Concore

Concore (bisoprolol fumarate) tablets must be stored according to official labeling to maintain their quality and strength.


Storage Requirements

Store the medicine at controlled room temperature, typically below 25 C to 30 C (77 F to 86 F), and do not freeze it. Protection from moisture and direct light is required. The tablets must remain in the original, tightly closed container and be kept strictly out of the sight and reach of children. Do not use the medicine after the labeled expiry date.


Disposal Instructions

Unused or expired tablets should not be disposed of via wastewater or regular household trash. Discarding the product must follow local pharmaceutical waste regulations or an official medicine take-back program to ensure environmental safety and prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Concore found in:

A-Z Index: